Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder

This study is currently recruiting participants.
Verified June 2013 by Elan Pharmaceuticals
Sponsor:
Collaborator:
Elan Pharmaceuticals
Information provided by (Responsible Party):
Elan Pharmaceuticals ( Elan Pharma International Limited )
ClinicalTrials.gov Identifier:
NCT01674010
First received: August 24, 2012
Last updated: June 11, 2013
Last verified: June 2013
  Purpose

The primary purpose of this study is to determine whether ELND005 is effective in the maintenance treatment of bipolar 1 disorder when added to other therapies.


Condition Intervention Phase
Bipolar 1 Disorder
Drug: ELND005
Drug: Lamotrigine
Drug: Valproic acid
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Safety and Efficacy Study of Oral ELND005 as an Adjunctive Maintenance Treatment in Patients With Bipolar I Disorder

Resource links provided by NLM:


Further study details as provided by Elan Pharmaceuticals:

Primary Outcome Measures:
  • Time to recurrence of any mood episode [ Time Frame: up to 48 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Proportion of study participants with recurrence of any mood episode [ Time Frame: up to 48 weeks ] [ Designated as safety issue: No ]
  • Time to recurrence of a depressive episode [ Time Frame: up to 48 weeks ] [ Designated as safety issue: No ]
  • Time to recurrence of a manic/hypomanic or a mixed episode [ Time Frame: up to 48 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 400
Study Start Date: August 2012
Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lamotrigine or Valproic acid + ELND005
Lamotrigine or valproic acid plus ELND005 film coated tablets, 500mg BID for up to 48 weeks
Drug: ELND005
Other Name: Scyllo-inositol
Drug: Lamotrigine Drug: Valproic acid
Placebo Comparator: Lamotrigine or Valproic acid + placebo
Lamotrigine or valproic acid plus matched placebo BID for up to 48 weeks
Drug: Lamotrigine Drug: Valproic acid Drug: Placebo

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Meets the DSM-IV-TR criteria for BPD I by the SCID, prior to the Screening Visit.
  • Has a history in the last 3 years of ≥ 1 manic or mixed episodes of sufficient severity that required hospitalization and/or treatment with a mood stabilizer or antipsychotic, or confirmed by a family member or medical records to ensure the episode fulfills the DSM-IV-TR criteria.
  • Has experienced a mood episode of any polarity within 4 months prior to the Screening Visit and responded to StOC therapy.
  • Is euthymic at the Screening Visit (ie, score of ≤ 12 on the MADRS and a score of ≤ 12 on the Y-MRS).
  • Is receiving maintenance treatment for his or her BPD I with either LTG or VPA; on stable doses for past 4 weeks and therapeutic drug levels (total VPA 50--125 µg/mL and LTG 10-50 µmol/L or as deemed appropriate by the investigator). Dose adjustments made for tolerability reasons will be acceptable.

A study patient must meet the following additional criteria to be eligible for randomization in the Double-blind Randomization Phase of this study:

- Maintained in a stable euthymic state during Phase 1, defined as Y-MRS and MADRS scores of ≤ 12, with the following exceptions: a maximum of 2 nonconsecutive excursions will be allowed throughout Phase 1. Excursions are defined as Y-MRS or MADRS scores >12 but ≤ 16.

Exclusion Criteria:

  • Woman of childbearing potential who is unwilling or unable to use an acceptable method of birth control or is using a prohibited contraceptive method.
  • Is found to be actively suicidal on the C-SSRS (answer of "yes" to question 4 or 5 [current or over the last 30 days]) or a score of ≥4 on the MADRS item 10 at the Screening Visit.
  • Has suboptimally treated thyroid disease as evidenced by thyroid-stimulating hormone (TSH) >3 mIU/L at the Screening Visit.
  • Has received electroconvulsive therapy (ECT) during the current episode or within 6 months prior to the Screening Visit.
  • Has an estimated glomerular filtration rate <40 mL/min/1.73 m2 according to the Modification of Diet in Renal Disease formula.

A study patient who meets ANY of the above and ANY of the criteria below will not be eligible for enrollment in the Double-blind Randomization Phase of this study:

  • Has current signs or symptoms of psychosis.
  • Has become actively suicidal as defined by C-SSRS answer of "yes" to question 4 or 5 (current or over the last 30 days) and/or has a score of ≥4 on MADRS item 10.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01674010

Contacts
Contact: Lisa Parsons 503-432-1754

  Hide Study Locations
Locations
United States, Alabama
Elan Investigational Site Recruiting
Birmingham, Alabama, United States, 35294
United States, Arizona
Elan Investigational Site Recruiting
Glendale, Arizona, United States, 85306
United States, Arkansas
Elan Investigational Site Recruiting
Little Rock, Arkansas, United States, 72211
Elan Investigational Site Recruiting
Little Rock, Arkansas, United States, 72201
United States, California
Elan Investigational Site Recruiting
Cerritos, California, United States, 90703
Elan Investigational Site Recruiting
Costa Mesa, California, United States, 92626
Elan Investigational Site Recruiting
Escondido, California, United States, 92025
Elan Investigational Site Recruiting
Garden Grove, California, United States, 92845
Elan Investigational Site Recruiting
National City, California, United States, 91950
Elan Investigational Site Recruiting
Oceanside, California, United States, 92056
Elan Investigational Site Recruiting
Palo Alto, California, United States, 94304
Elan Investigational Site Recruiting
Riverside, California, United States, 92506
Elan Investigational Site Recruiting
San Diego, California, United States, 92121
Elan Investigational Site Recruiting
Santa Ana, California, United States, 92701
United States, Connecticut
Elan Investigational Site Recruiting
Norwich, Connecticut, United States, 06360
United States, Florida
Elan Investigational Site Recruiting
North Miami, Florida, United States, 33161
Elan Investigational Site Recruiting
Tampa, Florida, United States, 33613
United States, Georgia
Elan Investigational Site Recruiting
Atlanta, Georgia, United States, 30308
Elan Investigational Site Recruiting
Roswell, Georgia, United States, 30076
United States, Missouri
Elan Investigational Site Recruiting
Creve Coeur, Missouri, United States, 63141
Elan Investigational Site Recruiting
St. Louis, Missouri, United States, 63118
Elan Investigational Site Recruiting
St. Louis, Missouri, United States, 63141
Elan Investigational Site Recruiting
St. Louis, Missouri, United States, 63128
United States, Nebraska
Elan Investigational Site Recruiting
Lincoln, Nebraska, United States, 68526
United States, New Jersey
Elan Investigational Site Recruiting
Marlton, New Jersey, United States, 08053
United States, New York
Elan Investigational Site Recruiting
Fresh Meadows, New York, United States, 11366
Elan Investigational Site Recruiting
New York, New York, United States, 10065
United States, North Carolina
Elan Investigational Site Recruiting
Raleigh, North Carolina, United States, 27609
United States, Ohio
Elan Investigational Site Recruiting
Beachwood, Ohio, United States, 44122
Elan Investigational Site Recruiting
Cincinnati, Ohio, United States, 45219
Elan Investigational Site Recruiting
Cleveland, Ohio, United States, 44106
United States, Oklahoma
Elan Investigational Site Recruiting
Oklahoma City, Oklahoma, United States, 73112
United States, Pennsylvania
Elan Investigational Site Recruiting
Philadelphia, Pennsylvania, United States, 19139
United States, South Carolina
Elan Investigational Site Recruiting
Charleston, South Carolina, United States, 29407
United States, Texas
Elan Investigational Site Recruiting
Hurst, Texas, United States, 76053
Elan Investigational Site Recruiting
San Antonio, Texas, United States, 78229
United States, Utah
Elan Investigational Site Recruiting
Salt Lake City, Utah, United States, 84106
United States, Washington
Elan Investigational Site Recruiting
Bellevue, Washington, United States, 98007
Bulgaria
Elan Investigational Site Recruiting
Kardzhali, Bulgaria, 6600
Elan Investigational Site Recruiting
Pazardzhik, Bulgaria, 4400
Elan Investigational Site Recruiting
Vratsa, Bulgaria, 3000
Canada, Alberta
Elan Investigational Site Recruiting
Edmonton, Alberta, Canada, T6L 6W6
Canada, British Columbia
Elan Investigational Site Recruiting
Kelowna, British Columbia, Canada, V1Y 1Z9
Canada, Nova Scotia
Elan Investigational Site Recruiting
Halifax, Nova Scotia, Canada, B3H 2E2
Canada, Ontario
Elan Investigational Site Recruiting
Chatham, Ontario, Canada, N7M 5L9
Elan Investigational Site Recruiting
Kingston, Ontario, Canada, K7L 4X3
Czech Republic
Elan Investigational Site Recruiting
Brno, Czech Republic, 602 00
Elan Investigational Site Recruiting
Litomerice, Czech Republic, 41201
Elan Investigational Site Recruiting
Praha, Czech Republic, 18100
Elan Investigational Site Recruiting
Praha, Czech Republic, 120 00
Elan Investigational Site Recruiting
Praha, Czech Republic, 100 00
Lithuania
Elan Investigational Site Recruiting
Kaunas, Lithuania, 50009
Romania
Elan Investigational Site Recruiting
Brasov, Romania, 500366
Elan Investigational Site Recruiting
Bucharest, Romania, 041914
Elan Investigational Site Recruiting
Craiova, Romania, 200473
Elan Investigational Site Recruiting
Sibiu, Romania, 550082
Spain
Elan Investigational Site Recruiting
Torrevieja, Alicante, Spain, 03186
Elan Investigational Site Recruiting
L'Hospitalet, Barcelona, Spain, 08907
Elan Investigational Site Recruiting
Barcelona, Spain, 08036
Elan Investigational Site Recruiting
Madrid, Spain, 28034
Elan Investigational Site Recruiting
Vitoria, Spain, 01004
Sponsors and Collaborators
Elan Pharma International Limited
Elan Pharmaceuticals
  More Information

No publications provided

Responsible Party: Elan Pharmaceuticals ( Elan Pharma International Limited )
ClinicalTrials.gov Identifier: NCT01674010     History of Changes
Other Study ID Numbers: ELND005-BPD201, 2012-001935-30
Study First Received: August 24, 2012
Last Updated: June 11, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Lamotrigine
Valproic Acid
Anticonvulsants
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
GABA Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Calcium Channel Blockers
Membrane Transport Modulators
Cardiovascular Agents

ClinicalTrials.gov processed this record on June 18, 2013